Payment overview · 2025
General Payments
$232.97
12 reported records · 7 companies
Healthcare provider profile · identity verified
Maria E Goleba, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DAVISON, MI · NPI 1306834429
Verified facts
What the public records show
CMS Open Payments records show Maria E Goleba, MD received $232.97 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.88 | 30.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.87 | 17.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.96 | 15.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.70 | 14.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.35 | 8.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.45 | 7.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.76 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $219.21 | 11 |
| Education | $13.76 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.02 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.02 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 275 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
275 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1127 | 348 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1083 | 282 |
| Losartan Potassium | Losartan Potassium | 675 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 581 | 188 |
| Lisinopril | Lisinopril | 564 | 165 |
| Omeprazole | Omeprazole | 549 | 158 |
| Metoprolol Succinate | Metoprolol Succinate | 485 | 147 |
| Metformin Hcl | Metformin Hcl | 457 | 132 |
| Simvastatin | Simvastatin | 422 | 107 |
| Gabapentin | Gabapentin | 402 | 98 |
| Glimepiride | Glimepiride | 395 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 377 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 358 | 114 |
| Clopidogrel | Clopidogrel Bisulfate | 322 | 84 |
| Potassium Chloride | Potassium Chloride | 311 | 99 |
| Furosemide | Furosemide | 298 | 93 |
| Ozempic | Semaglutide | 275 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 92 |
| Escitalopram Oxalate | Escitalopram Oxalate | 269 | 79 |
| Montelukast Sodium | Montelukast Sodium | 220 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 84 |
| Eliquis | Apixaban | 215 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 67 |
| Trazodone Hcl | Trazodone Hcl | 205 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 51 |
| Clonidine Hcl | Clonidine Hcl | 202 | 59 |
| Meloxicam | Meloxicam | 197 | 75 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 196 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 195 | 60 |
| Famotidine | Famotidine | 192 | 54 |
| Buspirone Hcl | Buspirone Hcl | 188 | 41 |
| Tramadol Hcl | Tramadol Hcl | 187 | 51 |
| Carvedilol | Carvedilol | 185 | 67 |
| Atenolol | Atenolol | 182 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 182 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 56 |
| Sertraline Hcl | Sertraline Hcl | 175 | 58 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 170 | 42 |
| Nifedipine Er | Nifedipine | 166 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 161 | 45 |
| Methylprednisolone | Methylprednisolone | 155 | 135 |
| Quetiapine Fumarate | Quetiapine Fumarate | 152 | 33 |
| Allopurinol | Allopurinol | 150 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 146 | 56 |
| Trulicity | Dulaglutide | 131 | 28 |
| Mirtazapine | Mirtazapine | 128 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 39 |
| Memantine Hcl | Memantine Hcl | 117 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 117 | 33 |
| Bupropion Xl | Bupropion Hcl | 112 | 37 |
| Ibuprofen | Ibuprofen | 110 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 105 | 33 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 99 | 27 |
| Azithromycin | Azithromycin | 99 | 74 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 24 |
| Spironolactone | Spironolactone | 99 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 87 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 69 |
| Paroxetine Hcl | Paroxetine Hcl | 81 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 29 |
| Alprazolam | Alprazolam | 78 | 32 |
| Januvia | Sitagliptin Phosphate | 75 | 19 |
| Prednisone | Prednisone | 74 | 46 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 74 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 56 |
| Finasteride | Finasteride | 72 | 16 |
| Metformin Hcl Er | Metformin Hcl | 72 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 18 |
| Ezetimibe | Ezetimibe | 68 | 25 |
| Cephalexin | Cephalexin | 65 | 56 |
| Alendronate Sodium | Alendronate Sodium | 64 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 20 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 61 | 16 |
| Donepezil Hcl | Donepezil Hcl | 60 | 21 |
| Celecoxib | Celecoxib | 59 | 15 |
| Bumetanide | Bumetanide | 57 | 19 |
| Glipizide | Glipizide | 57 | 15 |
| Pregabalin | Pregabalin | 57 | 14 |
| Jardiance | Empagliflozin | 55 | 21 |
| Valacyclovir | Valacyclovir Hcl | 55 | 22 |
| Xarelto | Rivaroxaban | 53 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 52 | 28 |
| Baclofen | Baclofen | 51 | 16 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 51 | 21 |
| Estradiol | Estradiol | 50 | 16 |
| Fluconazole | Fluconazole | 50 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 50 | 23 |
| Nystatin | Nystatin | 49 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 16 |
| Amoxicillin | Amoxicillin | 47 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 30 |
| Labetalol Hcl | Labetalol Hcl | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 15 |
| Metronidazole | Metronidazole | 46 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 14 |
| Enalapril Maleate | Enalapril Maleate | 44 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 12 |
| Meclizine Hcl | Meclizine Hcl | 44 | 28 |
| Warfarin Sodium | Warfarin Sodium | 43 | 13 |
| Acyclovir | Acyclovir | 41 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 17 |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 33 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 13 |
| Lidocaine | Lidocaine | 40 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | 11 |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Topiramate | Topiramate | 38 | 14 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 34 | 15 |
| Levofloxacin | Levofloxacin | 34 | 29 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 14 |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 13 |
| Mupirocin | Mupirocin | 29 | 22 |
| Ramipril | Ramipril | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Lactulose | Lactulose | 27 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | 24 |
| Sucralfate | Sucralfate | 27 | 12 |
| Tradjenta | Linagliptin | 26 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 13 |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | 12 |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Trivora-28 | Levonorgestrel/Ethin.Estradiol | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $232.97 · 12 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, EOHILIA, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR, Veozah, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error